8-K: NEXGEL Reports Record Second Quarter Revenue, Reaffirms Guidance

NEXGEL announced record second quarter 2024 revenue of $1.44 million, a 23.4% year-over-year increase, and reiterated revenue guidance for the third and fourth quarters.

Summary

• NEXGEL reported a record revenue of $1.44 million for the second quarter of 2024, marking a 23.4% increase compared to the same period last year and a 13.7% sequential increase.
• The company's branded consumer product revenue was a key driver, particularly from the Silly George brand, which contributed revenue for approximately half the quarter.
• Gross profit for the quarter was $410,000, up from $175,000 in the same quarter of the previous year, with a gross profit margin of 28.5%.
• Selling, general, and administrative expenses increased to $1.39 million, primarily due to increased advertising and marketing costs.
• The net loss for the quarter was $979,000, compared to a net loss of $642,000 in the second quarter of 2023.
• NEXGEL reaffirmed its revenue guidance for the third and fourth quarters of 2024, projecting $2.2 million and $2.6 million, respectively.
• The company closed a registered direct offering for gross proceeds of approximately $1.11 million, led by insiders, to support working capital and inventory needs.
• As of June 30, 2024, NEXGEL had a cash balance of approximately $1.1 million and believes it has sufficient cash to operate its business into 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with record revenue and reaffirmed guidance, but the increased net loss and expenses temper the overall sentiment. The capital raise is a positive sign of support from insiders.

Positives

• The company achieved record revenue for the second quarter of 2024.
• Branded consumer product sales, particularly from the Silly George acquisition, drove significant revenue growth.
• Gross profit and gross profit margin increased substantially year-over-year.
• The company has secured partnerships with STADA and Cintas for product distribution.
• NEXGEL successfully raised additional capital through a registered direct offering.
• The company is conducting a study on the benefits of hydrogel application during laser hair removal.

Negatives

• The company experienced a net loss of $979,000 for the quarter, an increase from the $642,000 loss in the same period last year.
• Selling, general, and administrative expenses increased significantly due to marketing and advertising costs.
• Contract manufacturing revenue decreased due to a facility move by CGN, although this is expected to normalize.
• Research and development expenses increased slightly.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• Increased selling, general, and administrative expenses may impact profitability.
• The company's ability to achieve its revenue guidance depends on various factors, including market demand and successful product launches.
• The company's reliance on key partnerships for distribution could pose a risk if those partnerships are not successful.

Future Outlook

NEXGEL has provided revenue guidance for the third and fourth quarters of 2024, projecting $2.2 million and $2.6 million, respectively. The company believes it has sufficient cash to operate its business into 2025.

Management Comments

• Adam Levy, NEXGEL's Chief Executive Officer, stated that the second quarter of 2024 was a record revenue quarter for the Company.
• Management is excited about the acquisition of Silly George and the revenue opportunities from partnerships with STADA and Cintas.

Industry Context

This announcement reflects a positive trend for NEXGEL in the healthcare and consumer product sectors, particularly with the growth in branded consumer products. The partnerships with STADA and Cintas indicate a strategic move to expand distribution channels and market reach.

Comparison to Industry Standards

• NEXGEL's 23.4% year-over-year revenue growth in Q2 2024 is strong compared to the average growth rate in the medical device and consumer health sector, which typically ranges from 5-15%.
• The gross profit margin of 28.5% is competitive, but still lower than some established players in the hydrogel market, such as Smith & Nephew, which often report gross margins above 50%.
• The company's net loss of $979,000 indicates that it is still in a growth phase and is investing heavily in marketing and expansion, which is common for companies of this size in the sector.
• The $1.11 million capital raise is relatively small compared to larger medical device companies, but is a positive step for a company of NEXGEL's size.

Stakeholder Impact

• Shareholders will likely view the record revenue and reaffirmed guidance positively.
• Employees may benefit from the company's growth and expansion.
• Customers will have access to new and innovative products through the company's partnerships.
• Suppliers may see increased demand for their products due to the company's growth.

Next Steps

• The company will focus on expanding sales of branded consumer products, particularly Silly George.
• NEXGEL will continue to develop and market its products through partnerships with STADA and Cintas.
• The company will continue the institutional review board study on hydrogel application during laser hair removal.

Key Dates

Keywords

NEXGEL, hydrogel, revenue, Silly George, financial results, gross profit, consumer products, STADA, Cintas, capital raise